Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products …
Biotechnology
IE, Dublin [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Alkermes plc (ALKS) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 546,933.92 | 25,910.83 | 2,951.31 | 1,380.47 | 1,136.74 | 0.00 | 10.5260 | 65.52 | -1.3084 | -11.5041 | -0.07 | -0.53 | 3.7034 | - - | ||
| Maximum | - - | - - | - - | 71,743,392.00 | 1,187,075.00 | 264,468.00 | 121,670.00 | 262,089.00 | 0.02 | 781.2500 | 3,715.80 | 1.0156 | 9.4181 | 0.41 | 26.76 | 73.1011 | - - | ||
| Minimum | - - | - - | - - | 0.00 | -149.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -857.2037 | -132.82 | -134.1667 | -716.7391 | -1.06 | -84.15 | 0.0000 | - - | ||
| Neurocrine Biosciences, Inc. NBIX | 137.55 | 0.70 0.51% | 962 vs. 951 | 13,926.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 101.00 | ||
| Intra-Cellular Therapies, Inc. ITCI | 83.23 | 1.45 1.77% | 691 vs. 560 | 8,823.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 106.00 | ||
| Alkermes plc ALKS | 28.54 | 0.07 0.25% | 1,208 vs. 1,673 | 4,617.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 161.00 | ||
| Amphastar Pharmaceuticals, Inc. AMPH | 35.25 | -0.18 -0.51% | 744 vs. 464 | 1,694.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 48.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.